Evonik has announced plans for the expansion of its Dossenheim and Hanau facilities in Germany in order to meet the increasing pharmaceutical demand for contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates in the European market.
With an investment of €25 million, the company is set to expand its facilities to increase the manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates in Germany.
The expansion will support complex customer projects, associated with oncological, antiviral, and other specialised drug products.The projects typically involve advanced technologies, including continuous processing, catalysis, and cryogenic chemistry.
This project will enhance the company’s position as atop global contract manufacturing organisation for APIs and intermediates.
This expansion is a much needed project to support customers seeking a trusted European site for the clinical and commercial production of their APIs and intermediates.
The first stage of the project is set to complete by middle of 2021, while the entire project is expected to be completed by 2024.